Literature DB >> 27917404

The Emerging Role of Cdk5 in Cancer.

Karine Pozo1, James A Bibb2.   

Abstract

Cdk5 is an atypical cyclin-dependent kinase that is well characterized for its role in the central nervous system rather than in the cell cycle. However Cdk5 has been recently implicated in the development and progression of a variety of cancers including breast, lung, colon, pancreatic, melanoma, thyroid and brain tumors. This broad pro-tumorigenic role makes Cdk5 a promising drug target for the development of new cancer therapies. Here we review the contribution of Cdk5 to molecular mechanisms that confer upon tumors the ability to grow, proliferate and disseminate to secondary organs, as well as resistance to chemotherapies. We subsequently discuss existing and new strategies for targeting Cdk5 and its downstream mechanisms as anti-cancer treatments.

Entities:  

Keywords:  Cdk5; cancer; resistance

Mesh:

Substances:

Year:  2016        PMID: 27917404      PMCID: PMC5132345          DOI: 10.1016/j.trecan.2016.09.001

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  92 in total

1.  A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion.

Authors:  Manuela Quintavalle; Leonardo Elia; Jeffrey H Price; Susanne Heynen-Genel; Sara A Courtneidge
Journal:  Sci Signal       Date:  2011-07-26       Impact factor: 8.192

Review 2.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

3.  AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.

Authors:  Yu Ren; Xuan Zhou; Juan-Juan Yang; Xia Liu; Xiao-hui Zhao; Qi-xue Wang; Lei Han; Xin Song; Zhi-yan Zhu; Wei-ping Tian; Lun Zhang; Mei Mei; Chun-sheng Kang
Journal:  Cancer Lett       Date:  2015-03-28       Impact factor: 8.679

Review 4.  Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells.

Authors:  Johanna Liebl; Robert Fürst; Angelika M Vollmar; Stefan Zahler
Journal:  Cell Signal       Date:  2011-06-30       Impact factor: 4.315

5.  CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive functions.

Authors:  María Florencia Ogara; Laura M Belluscio; Verónica de la Fuente; Bruno G Berardino; Silvina V Sonzogni; Laura Byk; Mariela Marazita; Eduardo T Cánepa
Journal:  Biochim Biophys Acta       Date:  2014-04-03

6.  Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.

Authors:  Fu-Ning Hsu; Mei-Chih Chen; Kuan-Chia Lin; Yu-Ting Peng; Pei-Chi Li; Eugene Lin; Ming-Ching Chiang; Jer-Tsong Hsieh; Ho Lin
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-08-13       Impact factor: 4.310

7.  CDK5 is a major regulator of the tumor suppressor DLC1.

Authors:  Brajendra K Tripathi; Xiaolan Qian; Philipp Mertins; Dunrui Wang; Alex G Papageorge; Steven A Carr; Douglas R Lowy
Journal:  J Cell Biol       Date:  2014-12-01       Impact factor: 10.539

8.  Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.

Authors:  Weiyan Xie; Chunhui Liu; Dan Wu; Zhenye Li; Chuzhong Li; Yazhuo Zhang
Journal:  Oncotarget       Date:  2016-08-09

9.  Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors.

Authors:  Sabine B Weitensteiner; Johanna Liebl; Vladimir Krystof; Libor Havlíček; Tomáš Gucký; Miroslav Strnad; Robert Fürst; Angelika M Vollmar; Stefan Zahler
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

10.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Authors:  Lydia Meder; Katharina König; Luka Ozretić; Anne M Schultheis; Frank Ueckeroth; Carsten P Ade; Kerstin Albus; Diana Boehm; Ursula Rommerscheidt-Fuss; Alexandra Florin; Theresa Buhl; Wolfgang Hartmann; Jürgen Wolf; Sabine Merkelbach-Bruse; Martin Eilers; Sven Perner; Lukas C Heukamp; Reinhard Buettner
Journal:  Int J Cancer       Date:  2015-09-25       Impact factor: 7.396

View more
  47 in total

1.  Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.

Authors:  Brett Lee Roach; Jordan Matthew Ngo; Clariss Limso; Koyinsola Bolutife Oloja; Deepali Bhandari
Journal:  Biochem Biophys Res Commun       Date:  2018-09-11       Impact factor: 3.575

2.  Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer.

Authors:  Louise J Jones; Claude Chelala; Emanuela Gadaleta; Pauline Fourgoux; Stefano Pirró; Graeme J Thorn; Rachel Nelan; Alastair Ironside; Vinothini Rajeeve; Pedro R Cutillas; Anna E Lobley; Jun Wang; Esteban Gea; Helen Ross-Adams; Conrad Bessant; Nicholas R Lemoine
Journal:  NPJ Breast Cancer       Date:  2020-08-21

Review 3.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

4.  Multisite Phosphorylation of S6K1 Directs a Kinase Phospho-code that Determines Substrate Selection.

Authors:  Abul Arif; Jie Jia; Belinda Willard; Xiaoxia Li; Paul L Fox
Journal:  Mol Cell       Date:  2019-01-03       Impact factor: 17.970

5.  Discovery of CDK5 Inhibitors through Structure-Guided Approach.

Authors:  Nishat Z Khair; Jimma L Lenjisa; Solomon Tadesse; Malika Kumarasiri; Sunita K C Basnet; Laychiluh B Mekonnen; Manjun Li; Sarah Diab; Matthew J Sykes; Hugo Albrecht; Robert Milne; Shudong Wang
Journal:  ACS Med Chem Lett       Date:  2019-03-20       Impact factor: 4.345

6.  Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.

Authors:  Hai Song; Chuwen Lin; Erica Yao; Kuan Zhang; Xiaoling Li; Qingzhe Wu; Pao-Tien Chuang
Journal:  J Biol Chem       Date:  2017-01-24       Impact factor: 5.157

7.  Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

Authors:  Samanta Sharma; Tian Zhang; Wojciech Michowski; Vito W Rebecca; Min Xiao; Roberta Ferretti; Jan M Suski; Roderick T Bronson; Joao A Paulo; Dennie Frederick; Anne Fassl; Genevieve M Boland; Yan Geng; Jacqueline A Lees; Rene H Medema; Meenhard Herlyn; Steven P Gygi; Piotr Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-19       Impact factor: 11.205

8.  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Authors:  Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

9.  Development of CDK2 and CDK5 Dual Degrader TMX-2172.

Authors:  Mingxing Teng; Jie Jiang; Zhixiang He; Nicholas P Kwiatkowski; Katherine A Donovan; Caitlin E Mills; Chiara Victor; John M Hatcher; Eric S Fischer; Peter K Sorger; Tinghu Zhang; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2020-06-03       Impact factor: 15.336

10.  Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.

Authors:  Tenley C Archer; Tobias Ehrenberger; Filip Mundt; Maxwell P Gold; Karsten Krug; Clarence K Mah; Elizabeth L Mahoney; Colin J Daniel; Alexander LeNail; Divya Ramamoorthy; Philipp Mertins; D R Mani; Hailei Zhang; Michael A Gillette; Karl Clauser; Michael Noble; Lauren C Tang; Jessica Pierre-François; Jacob Silterra; James Jensen; Pablo Tamayo; Andrey Korshunov; Stefan M Pfister; Marcel Kool; Paul A Northcott; Rosalie C Sears; Jonathan O Lipton; Steven A Carr; Jill P Mesirov; Scott L Pomeroy; Ernest Fraenkel
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.